Literature DB >> 11245433

Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients.

M R Spitz1, X Wu, Y Wang, L E Wang, S Shete, C I Amos, Z Guo, L Lei, H Mohrenweiser, Q Wei.   

Abstract

Sequence variations have been identified in a number of DNA repair genes, including XPD, but the effect of these polymorphisms on DNA repair capacity (DRC) is uncertain. We therefore examined XPD polymorphisms at Lys751Gln and Asp312Asn in 341 white lung cancer cases and 360 age-, sex-, ethnicity-, and smoking-matched controls accrued in a hospital-based molecular epidemiological study of susceptibility markers for lung cancer. As previously reported, DRC was statistically significantly lower in the cases than in the controls (7.8% versus 9.5%; P < 0.001), which represents an average 18% reduction among the cases. The variant Lys751Gln and Asp312Asn allele frequencies were 0.36 and 0.29, respectively, for the cases and 0.33 and 0.27, respectively, for the controls. For subjects homozygous for the variant genotype at either locus, the adjusted odds ratio [95% confidence interval (CI)] was 1.84 (1.11-3.04; P = 0.018, for trend). Both cases and controls with the wild-type genotypes exhibited the most proficient DRC. The risk (95% CI) for suboptimal DRC (defined as less than the median DRC value among the controls) was 1.57 (0.74-3.35) for those with the Gln/Gln751 genotype. For cases with the Asn/Asn312 genotype, the risk (95% CI) was 3.50 (1.06-11.59). For cases who were homozygous at either locus, the risk was 2.29 (1.03-5.12; P = 0.048, for trend). The pattern was less evident among the controls, although there was a nonsignificant 41% increase in the risk of suboptimal DRC for controls who were homozygous at either locus. These results suggest that the two XPD polymorphisms have a modulating effect on DRC, especially in the cases.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11245433

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  122 in total

1.  DNA repair capacity, DNA-strand break repair gene polymorphisms, and the incidence of hepatocellular carcinoma in southwestern Guangxi of China.

Authors:  Xiaoyun Zeng; Shun Liu; Hongping Yu; Long Ji; Longman Li; Jinmei Huang; Hua Bai; Xiaoqiang Qiu
Journal:  DNA Cell Biol       Date:  2012-06-12       Impact factor: 3.311

2.  No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: a meta-analysis.

Authors:  Ming Yin; Jingrong Yan; Alexandra Voutsina; Carmelo Tibaldi; David C Christiani; Rebecca S Heist; Rafael Rosell; Richard Booton; Qingyi Wei
Journal:  Lung Cancer       Date:  2010-11-13       Impact factor: 5.705

3.  APE1 Asp148Glu gene polymorphism and lung cancer risk: a meta-analysis.

Authors:  Ya-Nan Ji; Ping Zhan; Jing Wang; Li-Xin Qiu; Li-Ke Yu
Journal:  Mol Biol Rep       Date:  2010-12-04       Impact factor: 2.316

4.  DNA repair XRCC1 Arg399Gln polymorphism is associated with the risk of development of end-stage renal disease.

Authors:  Sinan Trabulus; Gulgun S Guven; Mehmet R Altiparmak; Bahadir Batar; Ozlem Tun; Ayse S Yalin; Aydin Tunckale; Mehmet Guven
Journal:  Mol Biol Rep       Date:  2012-06       Impact factor: 2.316

5.  Pharmacogenetics of oxaliplatin as adjuvant treatment in colon carcinoma: are single nucleotide polymorphisms in GSTP1, ERCC1, and ERCC2 good predictive markers?

Authors:  Arantza Fariña Sarasqueta; Gesina van Lijnschoten; Valery E P P Lemmens; Harm J T Rutten; Adriaan J C van den Brule
Journal:  Mol Diagn Ther       Date:  2011-10-01       Impact factor: 4.074

6.  Nucleotide excision repair polymorphisms and survival outcome for patients with metastatic breast cancer.

Authors:  Mary A Bewick; Robert M Lafrenie; Michael S C Conlon
Journal:  J Cancer Res Clin Oncol       Date:  2010-05-28       Impact factor: 4.553

Review 7.  Pharmacogenomics in colorectal cancer: the first step for individualized-therapy.

Authors:  Eva Bandrés; Ruth Zárate; Natalia Ramirez; Ana Abajo; Nerea Bitarte; Jesus Garíia-Foncillas
Journal:  World J Gastroenterol       Date:  2007-11-28       Impact factor: 5.742

8.  Gene polymorphisms predict toxicity to neoadjuvant therapy in patients with rectal cancer.

Authors:  Marjun P Duldulao; Wendy Lee; Rebecca A Nelson; Joyce Ho; Maithao Le; Zhenbin Chen; Wenyan Li; Joseph Kim; Julio Garcia-Aguilar
Journal:  Cancer       Date:  2012-10-23       Impact factor: 6.860

9.  Breast Cancer and DNA Repair Capacity: Association With Use of Multivitamin and Calcium Supplements.

Authors:  Yeidyly Vergne; Jaime Matta; Luisa Morales; Wanda Vargas; Carolina Alvarez-Garriga; Manuel Bayona
Journal:  Integr Med (Encinitas)       Date:  2013-06

10.  The association of ApE1 -656T>G and 1349T>G polymorphisms and idiopathic male infertility risk.

Authors:  Mostafa Yousefi; Zivar Salehi; Farhad Mashayekhi; Mohammad Hadi Bahadori
Journal:  Int Urol Nephrol       Date:  2015-04-28       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.